IL-35: A potential therapeutic target for controlling hepatitis B virus infection

Journal of Digestive Diseases

Volumn 16, Issue 1, 2015, Pages 1-6

  Xiang, Xiao Gang ^a   Xie, Qing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Hepatitis B virus; Human interleukin 35; Immunotherapy; ITr35; Regulatory T lymphocytes

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 35; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN;

ARTICLE; B LYMPHOCYTE; BIOLOGICAL ACTIVITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; CD4+ T LYMPHOCYTE; HEPATITIS B, CHRONIC; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY;

B-LYMPHOCYTES, REGULATORY; CD4-POSITIVE T-LYMPHOCYTES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNE TOLERANCE; INTERLEUKINS;

EID: 84925875466     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12218     Document Type: Article

References (84)

1. Collison LW, Workman CJ, Kuo TT etal. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-569.
2. Niedbala W, Wei XQ, Cai B etal. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007; 37: 3021-3029.
3. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol 2012; 13: 722-728.
4. Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family? Immunol Rev 2008; 226: 248-262.
5. Jones LL, Vignali DA. Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. Immunol Res 2011; 51: 5-14.
6. Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets 2009; 8: 40-52.
7. Oppmann B, Lesley R, Blom B etal. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-725.
8. Pflanz S, Timans JC, Cheung J etal. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity 2002; 16: 779-790.
9. Collison LW, Delgoffe GM, Guy CS etal. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 2012; 13: 290-299.
10. Olson BM, Sullivan JA, Burlingham WJ. Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front Immunol 2013; 4: 315.
11. Delgoffe GM, Murray PJ, Vignali DA. Interpreting mixed signals: the cell's cytokine conundrum. Curr Opin Immunol 2011; 23: 632-638.
12. Devergne O, Hummel M, Koeppen H etal. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 1996; 70: 1143-1153.
13. Devergne O, Birkenbach M, Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A 1997; 94: 12041-12046.
14. Schrader JW. Interleukin is as interleukin does. Trends Immunol 2002; 23: 573-574.
15. Allan SE, Zhao XS, Abraham T, McMurchy AN, Levings MK. Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3. Eur J Immunol 2008; 38: 3282-3289.
16. Bardel E, Larousserie F, Charlot-Rabiega P, Coulomb-L'Herminé A, Devergne O. Human CD4+CD25+Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol 2008; 181: 6898-6905.
17. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA. Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011; 186: 6661-6666.
18. Collison LW, Chaturvedi V, Henderson AL etal. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010; 11: 1093-1101.
19. Li X, Mai J, Virtue A etal. IL-35 is a novel responsive anti-inflammatory cytokine - a new system of categorizing anti-inflammatory cytokines. PLoS One 2012; 7: e33628.
20. Seyerl M, Kirchberger S, Majdic O etal. Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. Eur J Immunol 2010; 40: 321-329.
21. Ringkowski S, Thomas PS, Herbert C. Interleukin-12 family cytokines and sarcoidosis. Front Pharmacol 2014; 5: 233.
22. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 5: 521-531.
23. Langrish CL, McKenzie BS, Wilson NJ, Da Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004; 202: 96-105.
24. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007; 25: 221-242.
25. Banchereau J, Pascual V, O'Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 2012; 13: 925-931.
26. Yoshida H, Miyazaki Y. Regulation of immune responses by interleukin-27. Immunol Rev 2008; 226: 234-247.
27. Shen P, Roch T, Lampropoulou V etal. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014; 507: 366-370.
28. Wang RX, Yu CR, Dambuza IM etal. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 2014; 20: 633-641.
29. Mauri C, Nistala K. Interleukin-35 takes the 'B' line. Nat Med 2014; 20: 580-581.
30. Ye S, Wu J, Zhou L, Lv Z, Xie H, Zheng S. Interleukin-35: the future of hyperimmune-related diseases? J Interferon Cytokine Res 2013; 33: 285-291.
31. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-1151.
32. Gavin MA, Rasmussen JP, Fontenot JD etal. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007; 445: 771-775.
33. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
34. Gravano DM, Vignali DA. The battle against immunopathology: infectious tolerance mediated by regulatory T cells. Cell Mol Life Sci 2012; 69: 1997-2008.
35. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3: 253-257.
36. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006; 25: 195-201.
37. Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR, Vignali DA. The development and function of regulatory T cells. Cell Mol Life Sci 2009; 66: 2603-2622.
38. Belkaid Y, Chen W. Regulatory ripples. Nat Immunol 2010; 11: 1077-1078.
39. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 212: 28-50.
40. Chen W, Jin W, Hardegen N etal. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-1886.
41. Groux H, O'Garra A, Bigler M etal. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737-742.
42. Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med 2006; 354: 1166-1176.
43. Haque M, Fino K, Lei F, Xiong X, Song J. Utilizing regulatory T cells against rheumatoid arthritis. Front Oncol 2014; 4: 209.
44. Lozano R, Naghavi M, Foreman K etal. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
45. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-592.
46. Trépo C, Chan HLY, Lok A. Hepatitis B virus infection. Lancet 2014; 384: 2053-2063.
47. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229.
48. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009; 49 Suppl 5: S13-21.
49. You CR, Lee SW, Jang JW, Yoon SK. Update on hepatitis B virus infection. World J Gastroenterol 2014; 20: 13293-13305.
50. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012; 61: 1754-1764.
51. Bertoletti A, Maini MK, Ferrari C. The host-pathogen interaction during HBV infection: immunological controversies. Antivir Ther 2010; 15 Suppl 3: 15-24.
52. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012; 61 Suppl 1: i6-17.
53. Seetharam A, Perrillo R, Gish R. Immunosuppression in patients with chronic hepatitis B. Curr Hepatol Rep 2014; 13: 235-244.
54. Balmasova IP, Yushchuk ND, Mynbaev OA etal. Immunopathogenesis of chronic hepatitis B. World J Gastroenterol 2014; 20: 14156-14171.
55. Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 2010; 184: 7144-7153.
56. Kuo J, Nardelli DT, Warner TF, Callister SM, Schell RF. Interleukin-35 enhances Lyme arthritis in Borrelia- vaccinated and -infected mice. Clin Vaccine Immunol 2011; 18: 1125-1132.
57. Li Y, Wang Y, Liu Y etal. The possible role of the novel cytokines IL-35 and IL-37 in inflammatory bowel disease. Mediators Inflamm 2014; 2014: 136329.
58. Wirtz S, Billmeier U, McHedlidze T, Blumberg RS, Neurath MF. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology 2011; 141: 1875-1886.
59. Zandian M, Mott KR, Allen SJ, Dumitrascu O, Kuo JZ, Ghiasi H. Use of cytokine immunotherapy to block CNS demyelination induced by a recombinant HSV-1 expressing IL-2. Gene Ther 2011; 18: 734-742.
60. Bai J, Qiu SL, Zhong XN etal. Erythromycin enhances CD4+Foxp3+ regulatory T-cell responses in a rat model of smoke-induced lung inflammation. Mediators Inflamm 2012; 2012: 410232.
61. Bettini M, Castellaw AH, Lennon GP, Burton AR, Vignali DA. Prevention of autoimmune diabetes by ectopic pancreatic β-cell expression of interleukin-35. Diabetes 2012; 61: 1519-1526.
62. Lin Y, Huang Y, Lu Z etal. Decreased plasma IL-35 levels are related to the left ventricular ejection fraction in coronary artery diseases. PLoS One 2012; 7: e52490.
63. Liu JQ, Liu Z, Zhang X etal. Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis. J Immunol 2012; 188: 3099-3106.
64. Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ, McNeel DG. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol 2012; 189: 5590-5601.
65. Huang Y, Lin YZ, Shi Y, Ji QW. IL-35: a potential target for the treatment of atherosclerosis. Pharmazie 2013; 68: 793-795.
66. Mao H, Gao W, Ma C etal. Human placental trophoblasts express the immunosuppressive cytokine IL-35. Hum Immunol 2013; 74: 872-877.
67. Pope RM, Shahrara S. Possible roles of IL-12-family cytokines in rheumatoid arthritis. Nat Rev Rheumatol 2013; 9: 252-256.
68. Kochetkova I, Thornburg T, Callis G, Holderness K, Maddaloni M, Pascual DW. Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27. J Immunol 2014; 192: 804-816.
69. Thiolat A, Denys A, Petit M etal. Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine 2014; 69: 87-93.
70. Tirotta E, Duncker P, Oak J etal. Epstein-Barr virus-induced gene 3 negatively regulates neuroinflammation and T cell activation following coronavirus-induced encephalomyelitis. J Neuroimmunol 2013; 254: 110-116.
71. Zeng JC, Zhang Z, Li TY etal. Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol 2013; 6: 1806-1816.
72. Wong CK, Leung TF, Chu IM, Dong J, Lam YY, Lam CW. Aberrant expression of regulatory cytokine IL-35 and pattern recognition receptor NOD2 in patients with allergic asthma. Inflammation 2014. [Epub ahead of print].
73. Ma Y, Liu X, Wei Z etal. The expression of a novel anti-inflammatory cytokine IL-35 and its possible significance in childhood asthma. Immunol Lett 2014; 162: 11-17.
74. Chen C, Deng Y, Chen H etal. Decreased concentration of IL-35 in plasma of patients with asthma and COPD. Asian Pac J Allergy Immunol 2014; 32: 211-217.
75. Jafarzadeh A, Jamali M, Mahdavi R etal. Circulating levels of interleukin-35 in patients with multiple sclerosis: evaluation of the influences of FOXP3 gene polymorphism and treatment program. J Mol Neurosci 2014 [Epub ahead of print].
76. Jin P, Ren H, Sun W, Xin W, Zhang H, Hao J. Circulating IL-35 in pancreatic ductal adenocarcinoma patients. Hum Immunol 2014; 75: 29-33.
77. Nicholl MB, Ledgewood CL, Chen X etal. IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: Evidence for a role as an autocrine growth factor. Cytokine 2014; 70: 126-133.
78. Pan Y, Tao Q, Wang H etal. Dendritic cells decreased the concomitant expanded Tregs and Tregs related IL-35 in cytokine-induced killer cells and increased their cytotoxicity against leukemia cells. PLoS One 2014; 9: e93591.
79. Sun YX, Kong HL, Liu CF etal. The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia. Hum Immunol 2014; 75: 113-118.
80. Okamoto A, Fujio K, Okamura T, Yamamoto K. Regulatory T-cell-associated cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011; 2011: 463412.
81. Langhans B, Braunschweiger I, Arndt S etal. Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. Clin Sci (Lond) 2010; 119: 97-109.
82. Liu F, Tong F, He Y, Liu H. Detectable expression of IL-35 in CD4+ T cells from peripheral blood of chronic hepatitis B patients. Clin Immunol 2011; 139: 1-5.
83. Tsuda M, Zhang W, Yang GX etal. Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice. Hepatology 2013; 57: 806-816.
84. Wang Y, Dong J, Meng W etal. Effects of phased joint intervention on IL-35 and IL-17 expression levels in patients with portal hypertension. Int J Mol Med 2014; 33: 1131-1139.